公开(公告)号：US20170198010A1

公开(公告)日：2017-07-13

申请号：US15412760

申请日：2017-01-23

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE ,  Gaku NAKAYAMA

IPC: C07K7/06 ,  C12N5/0783 ,  A61K39/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  C07K14/705 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/1114 ,  C12N2502/1121 ,  G01N33/57407

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

公开(公告)号：US20200155596A1

公开(公告)日：2020-05-21

申请号：US16773487

申请日：2020-01-27

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YAMASHITA ,  Tomohisa WATANABE ,  Tetsuro HIKICHI

IPC: A61K35/14 ,  C12N15/09 ,  C12N5/10 ,  C07K7/08 ,  C07K7/06 ,  C07K16/18 ,  A61K48/00 ,  A61K39/00 ,  A61K35/12

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20160114018A1

公开(公告)日：2016-04-28

申请号：US14890146

申请日：2014-05-22

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Yasuharu NISHIMURA ,  Yusuke TOMITA ,  Masatoshi HIRAYAMA ,  Ryuji OSAWA

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K31/7088 ,  A61K35/17 ,  A61K35/26 ,  A61K38/00 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/65 ,  A61K2300/00

Abstract: Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, cervical cancer, cholangiocellular carcinoma, chronic myelocytic leukemia, colon cancer, rectum cancer, esophageal cancer, gastric diffuse-type cancer, non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), lymphoma, osteosarcoma, ovarian cancer, renal carcinoma, soft tissue tumor, testicular tumor, and HNC.

Abstract translation: 本文公开了具有Th1细胞诱导能力的分离的IMP-3衍生的表位肽。 这样的肽可被MHC II类分子识别并诱导Th1细胞。 在优选的实施方案中，本发明的这种肽可以与MHC II类分子混合结合并诱导除Th1细胞之外的IMP-3-特异性细胞毒性T淋巴细胞（CTL）。 因此，这样的肽适合用于增强受试者的免疫应答，并因此在癌症免疫治疗中尤其是用作癌症疫苗时使用。 本文还公开了编码由这些肽诱导的上述肽，APC和Th1细胞中的任何一种的多核苷酸以及与其相关的诱导方法。 包含任何前述组分作为活性成分的药物组合物可用于治疗和/或预防癌症或肿瘤，包括例如膀胱癌，宫颈癌，胆管细胞癌，慢性骨髓性白血病，结肠癌，直肠癌，食管癌 癌症，胃弥漫型癌，非小细胞肺癌（NSCLC），小细胞肺癌（SCLC），淋巴瘤，骨肉瘤，卵巢癌，肾癌，软组织肿瘤，睾丸肿瘤和HNC。

公开(公告)号：US20160008445A1

公开(公告)日：2016-01-14

申请号：US14772003

申请日：2014-03-11

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5154 ,  C07K7/06 ,  C07K14/47 ,  C07K16/18 ,  G01N33/505 ,  G01N33/57484

Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a metastatic- or post-operative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from KNTC2, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract translation: 本文描述了针对癌症的肽疫苗。 特别地，提供了衍生自KNTC2基因的分离的表位肽，其引发CTL并因此适用于癌症免疫治疗的上下文中。 本发明的肽包括来自KNTC2的多肽及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持原始序列的必需的CTL诱导性。 还提供了编码这种肽的多核苷酸以及包括任何这样的肽或作为活性剂的多核苷酸的药物组合物。 还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。 此外，本发明提供了用于治疗和/或预防（即预防）癌症（肿瘤）和/或预防其转移或手术后复发的方法以及诱导CTL的方法，方法 用于诱导抗肿瘤免疫，使用衍生自KNTC2的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

公开(公告)号：US20150231222A1

公开(公告)日：2015-08-20

申请号：US14667560

申请日：2015-03-24

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Tomoaki FUJIOKA ,  Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OSAWA ,  Midori SHIDA

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4703

Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.

Abstract translation: 本发明提供具有如SEQ ID NO：7,8,9,10,11,12,192,195,197,209,225,226,228,230,240,241,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,2 243,244,249,253,254或255，以及具有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失或加入，其中肽具有细胞毒性T细胞诱导性 。 本发明还提供用于治疗或预防与MPHOSPH1和/或DEPDC1的过度表达相关的疾病的药物，例如， 含有这些肽作为活性成分的癌症。 本发明的肽也可以用作疫苗。